Five devices that initially reached market via the de novo review pathway will be regulated as moderate-risk class II, the US Food and Drug Administration announced on 1 December. The affected devices cross a range of sectors, including neurological, orthopedic and anesthesiology products.
The de novo pathway was developed as an alternative to the PMA and 510(k) regulatory tracks for products that aren’t...